Cargando…
High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina
PURPOSE: The purpose of this study was to evaluate the efficacy of HDR brachytherapy for primary or recurrent vaginal cancer. METHODS: Between the years 2000 to 2006, 18 patients with primary or recurrent vaginal cancer were treated with brachytherapy (HDRB). Six patients had primary vaginal cancer...
Autores principales: | Beriwal, Sushil, Heron, Dwight E, Mogus, Robert, Edwards, Robert P, Kelley, Joseph L, Sukumvanich, Paniti |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270281/ https://www.ncbi.nlm.nih.gov/pubmed/18271958 http://dx.doi.org/10.1186/1748-717X-3-7 |
Ejemplares similares
-
Preoperative high dose rate brachytherapy for clinical stage II endometrial carcinoma
por: Shukla, Gaurav, et al.
Publicado: (2011) -
Brachytherapy for malignancies of the vagina in the 3D era
por: Glaser, Scott M., et al.
Publicado: (2015) -
Comparison of Locoregional Recurrence with Mastectomy vs. Breast Conserving Surgery in Pregnancy Associated Breast Cancer (PABC)
por: Beriwal, Sushil, et al.
Publicado: (2009) -
A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
por: Li, Shidong, et al.
Publicado: (2021) -
Complete Pathologic Response Following Neoadjuvant Chemoradiotherapy and High-Dose-Rate Brachytherapy for Locally Advanced Endometrial Carcinoma
por: Horne, Zachary, et al.
Publicado: (2015)